The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS).
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; MSD (Inst); Novartis; Pfizer
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Roche
Research Funding - Nippon Boehringer Ingelheim
 
Shingo Miyamoto
No Relationships to Disclose
 
Satoshi Oizumi
Honoraria - AstraZeneca; Lilly
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai/Roche; Kissei Pharmaceutical; Merck Serono; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Norio Okamoto
Honoraria - AstraZeneca
 
Hidetoshi Itani
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Taiho Pharmaceutical
Speakers' Bureau - Lilly Japan
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Meiji Seika Kaisha
 
Atsushi Nakamura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD
Consulting or Advisory Role - Kyowa Hakko Kirin
 
Yuichiro Hayashi
No Relationships to Disclose
 
Noriko Motoi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Covidien; Miraca Life Sciences; MSD; Novartis; Roche
Research Funding - NEC Corporation (Inst); Ono Pharmaceutical (Inst)
 
Genichiro Ishii
No Relationships to Disclose
 
Koichi Goto
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo